Silexion Therapeutics Ltd. (SLXN) Total Return Calculator with Dividends Reinvested

Silexion Therapeutics Ltd.

Popular:

The total return for Silexion Therapeutics Ltd. (SLXN) stock is -97.78% over the past 12 months. So far it's down 85.48% this year. The 5-year total return is -99.90%, meaning $10,000 invested in SLXN stock 5 years ago would be worth $10 today. Total return includes price appreciation plus reinvesting any dividends paid out.

If you invested $10,000 in SLXN 1 year ago, it would be worth $221 today — you'd have lost $9,779.

With Dividends Reinvested$221-97.79%

Price Only (No DRIP)$221-97.79%

Period2025-06-23 → 2026-06-22

Price

Total Return (DRIP)

S&P 500

If You Invested $10,000 in SLXN

1Y$222-$9,778 (-97.8%)-97.8% CAGR

3Y$10-$9,990 (-99.9%)-89.9% CAGR

5Y$10-$9,990 (-99.9%)-74.7% CAGR

10Y$10-$9,990 (-99.9%)-49.7% CAGR

15Y$10-$9,990 (-99.9%)-36.8% CAGR

20Y$10-$9,990 (-99.9%)-29.1% CAGR

30Y$10-$9,990 (-99.9%)-20.5% CAGR

Silexion Therapeutics Ltd. did not pay dividends during this period. Total return = price return.

Loading SLXN total return...

As of 2026-06-23

Returns at a Glance

Period	Total Return	CAGR	Price Only	Div. Contrib.	$10K →
YTD	-85.48%	—	-85.48%	—	$1,452
1Y	-97.78%	-97.78%	-97.78%	—	$222
3Y	-99.90%	-89.88%	-99.90%	—	$10
5Y	-99.90%	-74.70%	-99.90%	—	$10
10Y	-99.90%	-49.70%	-99.90%	—	$10
15Y	-99.90%	-36.75%	-99.90%	—	$10
20Y	-99.90%	-29.08%	-99.90%	—	$10
30Y	-99.90%	-20.47%	-99.90%	—	$10

Risk & Highlights

Best Year-88.55%2024

Worst Year-93.57%2025

Max Drawdown-98.55%2025-07-31 → 2026-01-24

Annual Returns

Year	Total Return	Price Return	Div.	S&P 500	vs S&P
2026YTD	-8.24%	-8.24%	—	+0.41%	-8.7pp
2025	-93.57%	-93.57%	—	+16.64%	-110.2pp
2024	-88.55%	-88.55%	—	+24.00%	-112.5pp

SLXN underperformed the S&P 500 by 122.77pp over the past year (-97.78% vs +24.99%).

Loading summary...

SLXN Peers' Total Return

Accurate peer set · 10 comparable names

Name	Mkt Cap	30D Rtn	YTD Total Rtn	1Y Total Rtn	Div Contrib	3Y Total Rtn	5Y Total Rtn	10Y Total Rtn
SLXNSilexion Therapeutics Ltd.	$872,200	-0.4%	-85.5%	-97.8%	—	-99.9%	-99.9%	-99.9%
SRPTSarepta Therapeutics, Inc.	$1.9B	+3.1%	-17.7%	-15.6%	—	-86.7%	-77.9%	-1.8%
ARWRArrowhead Pharmaceuticals, Inc.	$11.6B	+10.6%	+20.7%	+423.8%	—	+128.7%	-4.5%	+1291.5%
NTLAIntellia Therapeutics, Inc.	$1.8B	+23.5%	+70.1%	+63.2%	—	-64.1%	-79.4%	-43.2%
IONSIonis Pharmaceuticals, Inc.	$12.5B	+2.2%	-7.0%	+100.3%	—	+80.5%	+96.1%	+221.7%
REGNRegeneron Pharmaceuticals, Inc.	$63.6B	-3.1%	-21.2%	+19.5%	+0.7pp	-21.2%	+14.4%	+74.5%
MRNAModerna, Inc.	$23.5B	+32.9%	+107.3%	+151.8%	—	-48.5%	-67.9%	+243.9%
BEAMBeam Therapeutics Inc.	$3.7B	+27.3%	+25.8%	+100.9%	—	+2.4%	-59.8%	+82.1%
ILMNIllumina, Inc.	$24.5B	+14.4%	+20.5%	+79.4%	—	-17.6%	-63.5%	+18.9%
TMOThermo Fisher Scientific Inc.	$172.4B	+5.1%	-21.4%	+18.8%	+0.5pp	-11.0%	-2.2%	+220.6%
CRSPCRISPR Therapeutics AG	$5.2B	+11.4%	+0.6%	+21.7%	—	-4.9%	-57.7%	+283.9%

Compare:SLXN vs SRPT SLXN vs ARWR SLXN vs NTLA SLXN vs SRPT vs ARWR

About SLXN Dividend Returns

Silexion Therapeutics Ltd. (SLXN) does not currently pay dividends. Many growth-focused companies reinvest profits back into the business rather than distributing them as dividends.

How We Calculate Total Return

Our total return calculator simulates dividend reinvestment (DRIP) by assuming each dividend payment is used to purchase additional shares at the closing price on the ex-dividend date. This methodology provides an accurate representation of how a dividend reinvestment plan would perform.

Frequently Asked Questions

Q1What is the total return of SLXN over the past year?

Silexion Therapeutics Ltd. (SLXN) delivered a return of -97.78% over the past year. Since SLXN does not currently pay dividends, the total return equals the price-only return.

Q2How much would $10,000 invested in SLXN be worth today?

A $10,000 investment in Silexion Therapeutics Ltd. one year ago would be worth $222 today, representing a loss of $9,778.

Q3Does SLXN pay dividends?

Silexion Therapeutics Ltd. (SLXN) does not currently pay dividends. Many growth-focused companies reinvest profits back into the business rather than distributing them as dividends. For SLXN, the total return equals the price-only return.

Q4Did SLXN beat the S&P 500?

No, Silexion Therapeutics Ltd. (SLXN) underperformed the S&P 500 by 122.77 percentage points over the past year. SLXN delivered a total return of -97.78%, compared to the S&P 500's 24.99%. This means a passive S&P 500 index fund outperformed SLXN by 122.77pp during this period.

Q5What is SLXN's worst drawdown?

Silexion Therapeutics Ltd. (SLXN) experienced a maximum drawdown of -98.55% over the past year, declining from its peak on 2025-07-31 to its trough on 2026-01-24. The stock has not yet fully recovered to its prior peak. Maximum drawdown measures the worst peak-to-trough decline and is an important risk metric for investors.

Q6What is SLXN's long-term total return over 10, 20, or 30 years?

Here are Silexion Therapeutics Ltd. (SLXN)'s long-term returns with dividends reinvested. Over 10 years, the total return is -99.9% (-49.7% CAGR) — $10,000 would have grown to $10. Over 20 years: -99.9% total return (-29.1% CAGR) — $10,000 → $10. Over 30 years: -99.9% total return (-20.5% CAGR) — $10,000 → $10. Long-term investors benefit from compounding: dividends buy additional shares, which generate their own dividends, creating an exponential growth effect.

Q7What was SLXN's best and worst year?

Silexion Therapeutics Ltd.'s best calendar year was 2024 with a total return of -88.5%. Its worst year was 2025 with a total return of -93.6%. This range shows the volatility investors should expect — the difference between the best and worst year is 5.0 percentage points.

How much would $100/month in SLXN be worth today?

Dollar cost averaging calculator · DCA vs lump sum · see how regular investing compounds

Run the Numbers →